

RESTRICTED BENEFIT CRITERIA - WIXELA®

PROVINCE/PROGRAM	INDICATION	CRITERIA
Alberta ST/SA	ASTHMA	Asthma uncontrolled on ICS
	COPD 250/50 and 500/50 mcg	Moderate to severe COPD uncontrolled on LABA or LAMA Severe COPD treated with LAMA or LABA
British Columbia SA	ASTHMA	Asthma uncontrolled on ICS
	COPD	Moderate to very severe COPD exacerbating on LABA or LAMA
New Brunswick SA	ASTHMA	Asthma uncontrolled on ICS Asthma controlled on ICS/LABA
	COPD	As part of an open triple therapy in COPD uncontrolled on LAMA/LABA
	ACO	In patients with an asthma/COPD overlap
Non-insured health benefits LU	ASTHMA	Asthma uncontrolled on medium dose ICS
	COPD	Moderate to severe COPD COPD uncontrolled on LAMA or LABA
Newfoundland and Labrador SA	ASTHMA	Asthma symptomatic on ICS
	COPD	As part of an open triple therapy in COPD uncontrolled on LAMA/LABA
	ACO	In patients with an asthma/COPD overlap
Nova Scotia EDS	ASTHMA	Asthma symptomatic on ICS
	COPD	As part of an open triple therapy in COPD uncontrolled on LAMA/LABA
	ACO	In patients with an asthma/COPD overlap
Ontario LU Code	ASTHMA	330 Asthma symptomatic on ICS
Quebec RAMQ Code	ASTHMA	RE41 Asthma uncontrolled on ICS
	COPD	RE172 COPD exacerbating on dual bronchodilation (LAMA/LABA) or with an asthma component RE173 COPD prescription renewal (RE172)
Prince Edward Island SA	ASTHMA	Asthma uncontrolled on ICS
	COPD	As part of an open triple therapy in COPD uncontrolled on LAMA/LABA
	ACO	In patients with an asthma/COPD overlap
Saskatchewan EDS	ASTHMA	Asthma uncontrolled on ICS
	COPD	COPD treated with LAMA or LABA
Yukon EDS	ASTHMA	Asthma symptomatic on ICS
	COPD 250/50 and 500/50 mcg	Moderate to severe COPD exacerbating on LABA or LAMA for at least 6 months

ACO: asthma COPD overlap, COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, LU: limited use, RAMQ: Régie de l'assurance maladie du Québec, SA: Special Authorization, ST: Step therapy